Background: The use of Long-Acting Injectable (LAI) antipsychotic medications has increased for patients with Serious Mental Illness (SMI). Care coordination for this population is complex, and pharmacist involvement may improve and support long-term medication adherence and patient outcomes. Objectives: (1) Examine pharmacists' role in addressing care coordination and adherence challenges for patients taking Long-Acting Injectable (LAI) antipsychotics; and (2) explore patients' medication use experiences with LAI antipsychotics and educational needs. Methods: This project utilized a holistic work systems approach to assess the usefulness of implementing a pharmacist-led intervention to improve care coordination for patients taking LAI antipsychotics. Data collection and analyses were guided by the Systems Engineering Initiative for Patient Safety (SEIPS) model. Data were collected using interviews with healthcare team members and patients taking LAI antipsychotics and retrospective chart reviews at a psychiatric hospital in Southwestern Pennsylvania. Data collection elicited information about LAI care coordination, the pharmacist's role, and patients' experiences. Content and thematic analyses were conducted to identify opportunities to improve quality of care and patient outcomes. Results: Sixteen healthcare team members and six patients were interviewed. Twenty patient charts were reviewed to examine the care coordination process. Four themes of the workflow process emerged: pharmacist consultation, in-hospital LAI administration, discharge planning, and outpatient treatment. Key challenges identified included inadequate communication, limited knowledge, and the need for standardized roles. Most patients did not know the name of their LAI antipsychotic and did not recall receiving medication counseling, but were interested in discussing medication concerns with pharmacists. Conclusions: There is a need for improved communication during LAI care coordination, targeted education for healthcare team members, and standardization of roles. Many patients did not have adequate LAI antipsychotic knowledge or receive appropriate medication counseling. Increased pharmacist involvement in the care coordination process may promote adherence and optimal management of SMI.
Introduction
Serious Mental Illness (SMI), such as schizophrenia and bipolar disorder, significantly contributes to the international disease burden, even greater than HIV/AIDS, transportation injuries, tuberculosis, or diabetes. 1 An important aspect of the complex treatment for individuals with SMI is the use of antipsychotic medications. Antipsychotic medications are an effective treatment modality for preventing relapse and further progression of SMI. 2 However, medication adherence in patients with SMI is poor and high rates of relapse and morbidity persist. Many individual patient variables, illness characteristics, and environmental factors have been identified as determinants of nonadherence in this patient population. Medication-related factors, including side effects, complex regimens, frequency of administration, and cost present additional barriers to appropriate medication use. 3 To simplify medication administration and promote adherence, depot formulations of two Long-Acting Injectable (LAI) antipsychotics were developed in the 1960s. 4 Consequently, the US Food and Drug Administration approved eight additional LAI antipsychotics. LAI antipsychotics reduce administration from daily (oral formulations) to as infrequently as four times per year. In practice, LAI antipsychotics have become a mainstay of therapy for those with known nonadherence to oral formulations and an important component of recovery for patients with SMI. 5, 6 Although there was anticipation for improved medication adherence with the introduction of LAI antipsychotics with fewer extrapyramidal side effects, numerous studies have found that adherence is relatively unchanged compared to oral formulations. 7 The increasing use of LAI antipsychotics presents new challenges for healthcare team members involved in the care of patients with SMI. Effective treatment with LAI antipsychotics requires continuous care coordination, which is multifaceted and complex. 4 For patients beginning therapy during hospitalization, the continuum of care often begins with the inpatient psychiatrist's decision to initiate a LAI antipsychotic and then extends to the outpatient setting where therapy is to be continued following discharge. High medication costs, patient perceptions of treatment and access to healthcare team members trained to administer injections may lead to discontinuation of LAI antipsychotics across all levels of care. 7 Nonadherence due to inadequate transitions in care, incomplete outpatient care plans, and lack of adequate patient education may contribute to relapses and re-hospitalizations, thus imposing a significant financial burden on the healthcare system and reducing patient quality of life. 5,8e14 For instance, Veterans Affairs Medical Centers have recognized the need to improve care coordination by implementing interdisciplinary transitions-in-care programs involving physicians, nurse practitioners, case managers, pharmacists, and social workers. 15 This program is coordinated for each patient by a nurse case manager and involves numerous interventions, including medication management, transition planning, followup care, and communication across providers and organizations. 15 These programs have significantly reduced hospitalizations and emergency department visits, healthcare costs, and improved patient satisfaction with care. 15 The effectiveness of this intervention shows the potential for a similar impact in other healthcare settings in the private sector and benefit for the patients and organization. The key to optimizing antipsychotic treatment, including LAIs, is to ensure long-term medication continuation. 16 The challenges surrounding care coordination for patients on LAI antipsychotic therapy present pharmacists with an opportunity to assume new roles in patient care. 6 Pharmacists are well-positioned to assess the appropriateness of LAI therapy, provide patient medication counseling, participate in routine monitoring, and facilitate continuity of care for patients with SMI. Further investigation is needed to understand factors that contribute to patients' long-term adherence to LAI antipsychotic treatment. 4 The purpose of this project was to examine the current process for providing care to patients initiated on LAI antipsychotics during hospitalization and subsequently transitioned from hospital to home. Using a work systems approach, this project aimed to better understand the role of pharmacists in the care coordination process to improve the quality of patient care and support long-term adherence to LAI antipsychotics. Accordingly, the objectives of this project were to (1) examine pharmacists' role in addressing care coordination and adherence challenges for patients taking LAI antipsychotics; and (2) explore patients' medication use experiences with LAI antipsychotics and educational needs.
Material and methods

Conceptual model
This project utilized a holistic work systems approach to assess the usefulness of implementing a pharmacist-led intervention to improve care coordination for patients taking LAI antipsychotics. 17, 18 By describing the way a system functions, the work systems approach can detect difficulties and areas of improvement with an understanding of how changes may affect other parts of the system. 17, 18 We applied the SEIPS (Systems Engineering Initiative for Patient Safety) 2.0 work systems model in this project because it has been successful and widely utilized in health services research. 19 The SEIPS model has also been used in community pharmacy-based research. 18, 20 This model is based upon principles of human factors engineering and has five central components of the sociotechnical work system: person(s), organization, tools and technology, tasks, and environment. 17 The SEIPS model has been used to understand the relationships of these work system components and how their interactions impact the process of "work" by members of the system. This includes professional work by healthcare team members, patient work, and collaborative professional-patient work. These work processes result in outcomes at the patient, professional, and organizational levels. 18 Prior research applied the SEIPS model to the work of ICU nurses and care managers coordinating care for patients with chronic conditions and identified study performance obstacles in all five sociotechnical components of the model (person(s), organization, tools and technology, tasks, and environment). 17 Another study utilized the SEIPS model and targeted "patient work" to identify factors that influence patient engagement and self-management of chronic illness. 21 This study found that patient-specific factors that influenced patients' engagement and chronic illness self-management included the work system components of person(s), tasks, and tools of the SEIPS model. 21 For the purposes of this project, the SEIPS model was used to understand both individual and collaborative "work" processes of pharmacists and patients involved in LAI care coordination. Since patients with SMI are a central part of the care process and disease self-management, it is necessary to understand their perspectives and work within the system, on both individual and collaborative levels.
Setting
The project site was an urban, psychiatric hospital located in Southwestern Pennsylvania. This hospital is part of an extensive network of inpatient and outpatient psychiatric services, which provides care to more than 25,000 patients each year. Pharmacists are members of the interprofessional care team in both the inpatient and outpatient setting. Outpatient services were located within walking distance of the hospital, and included an off-site outpatient pharmacy, as well as numerous ambulatory psychiatric clinics and programs. These outpatient services were utilized by approximately 50% of patients discharged from the psychiatric hospital. The comprehensive inpatient and outpatient services supported the assessment of LAI care coordination across these levels of care. The hospital's Quality Improvement Committee approved this project.
Intervention
In July 2014, the pharmacy department at the psychiatric hospital implemented a new pharmacist consult intervention to reduce inappropriate use and pharmacy drug cost associated with inpatient LAI antipsychotic treatment. This intervention sought to ensure the continuum of care into the outpatient setting for patients initiated on a LAI antipsychotic during their inpatient stay. The intervention required the prescribing inpatient psychiatrist to order a pharmacy consult in the Electronic Health Record (EHR) for all LAI antipsychotic orders. A hardcopy of the consult form was sent to the inpatient pharmacy and a clinical pharmacist was assigned to complete the consult. The psychiatrist also completed a LAI approval form that detailed additional patient information, insurance coverage, reason for use, plans for medication administration, and continuity of care. The inpatient clinical pharmacist evaluated the consult and LAI approval forms to either approve, deny, or request additional information or modifications for the prescribed LAI antipsychotic. To approve the use of a LAI antipsychotic before it was administered in the inpatient setting, the pharmacist identified (1) the patient's established efficacy and tolerability of the oral formulation, (2) prescription insurance coverage verification, (3) a plan for continued outpatient treatment, (4) a clear timeframe for discharge, and (5) a reasonable expectation of compliance to the LAI antipsychotic.
After the inpatient use of a LAI antipsychotic was approved, the administration of the first injection occurred while the patient was still hospitalized or following discharge in the "day-of-discharge" injection clinic. The "day-of-discharge" injection clinic was a recent development that allowed the hospital to provide the patient with one injection before leaving the facility. Nurses administered all day-of-discharge injections. If inpatient or day-of-discharge injection requests were denied, the patient would receive their first injection in the outpatient setting.
A pharmacist-led transitions in care program that provided medication delivery and counseling prior to hospital discharge was available for all patients. The inpatient treatment team on each unit largely influenced the utilization of these pharmacy services. Following discharge from the hospital, patients continued psychiatric treatment in the outpatient setting and received their LAI antipsychotic in an injection clinic staffed with trained nurses. Patients either stayed within the hospital health system or received outpatient care outside of the network. Outpatient follow-up was more effective for patients that remained within the network, as those who did not were frequently lost during follow-up. As part of the requirements for approval of LAI use during the pharmacy consultation, all outpatient follow-up appointments should have been scheduled prior to initiating the LAI antipsychotic, permitting that the patient intended to follow-up within the network. The pharmacist consultation intervention created an ideal opportunity to explore the role of clinical pharmacists in facilitating appropriate use of LAI antipsychotics in the inpatient setting, and their impact on continuation of care upon discharge.
Data collection
Data collection occurred from December 2014 through April 2015. Data were collected using key informant interviews and retrospective chart reviews to understand the overall LAI care coordination process.
Interviews
The research team developed interview guides guided by the SEIPS model for healthcare team members and patients; questions were designed to elicit the process of LAI care coordination, barriers and facilitators of this work system process, and their experiences with LAI antipsychotics. Patients were eligible if they were 18 or older, discharged from the psychiatric hospital between July 2014 and January 2015, and treated with a LAI antipsychotic during the project period. The hospital pharmacy director and outpatient pharmacy manager identified eligible participants and facilitated recruitment. The hospital pharmacy director compiled a list of inpatient and outpatient healthcare team members involved in the care of patients treated with a LAI antipsychotic who also had a role in the pharmacist consult intervention. All healthcare team members on this list were contacted by a research team member to schedule an interview. Healthcare team members included psychiatrists, nurses, pharmacists, pharmacy technicians, and social workers. Members of the research team conducted semi-structured interviews using open-ended questions with healthcare team members and these interviews lasted~20 minutes. Healthcare team member interviews were audio recorded and professionally transcribed. Patients were asked during scheduled injection appointments if they were willing to participate in an interview regarding their LAI antipsychotic. Members of the research team conducted semi-structured interviews using open-ended and multiple choice questions with patients between January and March 2015, each lasting~5 minutes. Data were documented using a structured interview guide.
Retrospective chart reviews
Patients hospitalized from the beginning of the LAI intervention in July 2014 until January 2015 were initially identified for chart reviews. These patients were 18 years or older and were either (1) previously prescribed a LAI antipsychotic with a request to continue injections during inpatient treatment; or (2) newly prescribed a LAI antipsychotic with a request submitted to the pharmacy to initiate inpatient therapy. The inpatient pharmacy team compiled an MS Excel document of all 83 patients admitted to the facility that met these criteria. The list of patients was in numerical order from the beginning of the pharmacist consult intervention in July 2014 to January 2015 when chart review began. Patient charts were randomly selected from this list during the beginning, middle, and end of the six-month project timeframe for review.
Initially using five charts, the chart review template was developed and piloted by the research team, which included pharmacists (OA, JM, TF), a pharmacy student (MM), an industrial engineer (BN) and an engineering student (CB) to include both pharmacy and systems engineering perspectives. Based upon clinical evaluations by the healthcare team, 20 charts were reviewed to identify potential factors that may impact care coordination, such as medication name, rationale for use, past history of LAI antipsychotic use, insurance coverage, continuity of care plan, psychiatric readmissions, process barriers and facilitators, and additional comments regarding the medication use process. MM performed chart reviews at different times within the project period to ensure that data collected were reflective of progression of the LAI intervention. To ensure the quality of chart reviews, MM met weekly with OA to discuss chart review findings and progress; MM and CB met weekly to discuss chart review findings and review charts as needed. Data were documented and maintained in MS Excel and Word. Data collection was completed when saturation was reached for chart reviews and interviews, defined as the point at which no new information was obtained. 22 
Data analysis
The SEIPS model guided data analysis; the research team met weekly to discuss preliminary findings. We used a multiple triangulation approach by using multiple methods of data collection (interviews and chart reviews), multiple sources of data (healthcare team members and patients), and multiple investigators with differing areas of expertise in pharmacy and engineering. 23, 24 This is an ideal approach to support the credibility and trustworthiness of findings, and allow for cross-validation of qualitative themes during data analysis by identifying the most significant results. 23, 25 Content and thematic analyses were used to identify prevalent themes within the data related to challenges in LAI care coordination, recommendations for pharmacist involvement, and patients' experiences with use of LAI antipsychotics. Interview transcripts were analyzed independently by MM and CB. Chart review data provided validity to the information obtained during the interviews described in the prevalent themes below. The research team reached a consensus on major themes and subthemes of the LAI care coordination process, which were categorized using constructs of the SEIPS model. All data analyses was conducted using MS Excel and Word.
Results
Characteristics of the 16 healthcare team members interviewed are shown in Table 1 . Four themes emerged as key workflow processes which focused on (1) pharmacist consultation; (2) inhospital injection administration; (3) discharge; and (4) outpatient treatment. Challenges and facilitators of LAI care coordination were reported by healthcare team members in each of the five components of the SEIPS model (person(s), organization, tools and technology, tasks, and environment), as shown in Fig. 1 . Challenges and facilitators of each theme are described below with verbatim quotes.
Challenges and facilitators of pharmacist consultation
Psychiatrists and nurses reported apprehensiveness to mandatory pharmacist consultation and approval prior to LAI use. Reasons noted for apprehension included reduced prescribing control, feelings of challenged decision-making, concern for patients' discontinued LAI antipsychotics, additional paperwork, changing workflow, and delays due to the time consuming process. "I'm scared of [the LAI] being stopped and then the patient will then never go on it again." ePsychiatrist "It was a little bit strange and jarring to suddenly be working with pharmacists."e Psychiatrist Pharmacists perceived that psychiatrists were cautious of their involvement and provision of recommendations for LAI antipsychotic treatment.
"This is the first time we've really been so involved in actually controlling whether a medication gets started, and when it gets started. So I think that's a difficult thing for some of the prescribers to kind of wrap their head around." e Pharmacist "I think there's been also some physicians perceiving it as pharmacy manning the door. They don't feel that pharmacy should be telling them what is best for their patient."e Pharmacist However, some healthcare team members welcomed pharmacist involvement and chose to work with the pharmacy to address concerns and improve care coordination.
"I love them. We use it every time we can. They're the most helpful human beings in the hospital. I give them five stars. There are lots of steps and prior authorizations that would take us hours to figure out." e Psychiatrist One healthcare team member suggested that language and approach may be a factor in psychiatrists' receptiveness to pharmacist consultation and involvement.
"'You must' or 'you should,' physicians were not taking warmly to that language. Recommendations, and options within those recommendations, I think has worked better so I think the language has been an important thing." e Psychiatrist Time constraints were identified as a prominent reason for challenges with pharmacist involvement in care coordination. All healthcare team members reported that the current process was time consuming. The additional time required for the pharmacist consultation has resulted in a delay of medication administration for some patients. During patient chart review within EHR documentation, psychiatrists referenced "delays with hospital pharmacy or paperwork" as reasons for late or omitted injections. Multiple factors contributed to this delay including submission of incomplete LAI request forms or EHR documentation, and indirect communication among healthcare team members.
"So I think our issue would be just the length of time that it takes." e Nurse "I feel like it's a very labor intensive [process] for pharmacy." e Pharmacist "The more information they put, the smoother the consult goes, we do have some [psychiatrists] who are a little bit more resistant to the process so they just write some stuff down and then send it off. And then I have to e-mail back." e Pharmacist Most healthcare team members stated that LAI antipsychotics are 'outpatient medications' that required little or no inpatient oversight to initiate if the patient was already taking the equivalent oral formulation.
"[A LAI is] definitely something we want to think about closer to discharge, being that this is really your outpatient type medication." e Pharmacist "I think [psychiatrists] feel better for giving somebody an injection [inpatient] , but it doesn't really affect patient care." e Psychiatrist Conversely, some healthcare team members suggested strengths of the inpatient administration included a psychological benefit to the patient, an opportunity to observe the patient postinjection, and time for required overlap of some oral formulations.
"Some institutions have said 'these are outpatient medications, we're no longer going to offer them as inpatient therapy.' But we know that there are some instances where it is appropriate and in the best interest of the patient to have the long-acting started before they're discharged." e Pharmacist "[In the inpatient setting] it's the coordination aspect. The opportunity to provide the education, consent the patient, and then get the medication from pharmacy over the course of a day or two, and have them continue to talk about it and accept it."e Psychiatrist
Healthcare team members reported a lack of understanding of appropriate LAI antipsychotic use by other healthcare team members, and suggested that the complex care coordination required for appropriate use is often underestimated. "There's a severe lack of knowledge when it comes to the oral and the injectable."e Pharmacist "It can be difficult to understand how best to utilize these medications." e Psychiatrist "The coordination of it all. It's pretty tricky. Social workers have to be in on it, [pharmacy] has to be in on it, the doctors have to be in on it, the nurse managers have to bedyou know, it is a pretty tricky multidisciplinary project. All hands need to be in it, and all of them need to know what each other are doing." e Nurse Some healthcare team members reported that LAI antipsychotics were frequently perceived by prescribers as a solution for nonadherence, however they may cause inappropriate use and treatment failure in patients with inadequate social support.
"Putting somebody on a long-acting injectable does not substitute for social supports. It doesn't substitute for the services necessary to help the patient stay engaged. The injection is not a panacea and sometimes I don't know if inpatient doctors are in touch with all of that." e Psychiatrist
The use and accessibility of patient information in the EHR was reported by some healthcare team members to be beneficial during the pharmacist consultation and the overall care coordination process. "Opening the lines of communication between pharmacy, between physicians, and also patients. More responsibility in that communication." e Pharmacist "I think it's great in terms of everybody being on the same page, and that there is discussion." e Nurse
Challenges and facilitators of in-hospital injection administration
The pharmacy team was supportive of the patient receiving the injection before transitioning home. Psychiatrists' perceptions varied; some reported satisfaction with patients' ability to receive day-of-discharge injections in the clinic before leaving the facility, while others disagreed with first-time administration outside of the controlled, inpatient setting.
"I think that [psychiatrists] are a little bit more comfortable overall now that a lot of patients are beginning to get that day of discharge injection." e Psychiatrist "I'm not sure that the value of those day-of discharge injections was clearly established. If people are in the hospital for a while after their first injection [we] can monitor for adherence, their acceptance of the shot, for side effects, start tapering oral medications during that time, that might be more useful." e Psychiatrist Many healthcare team members also suggested a need for education concerning the purpose and process of LAI antipsychotic administration on the day-of-discharge. Some participants stated that social workers were responsible for facilitating the majority of the preparation for day-of-discharge injections, however social workers who participated were unsure of the totality of their role in the process.
"I think it just seems that with the [day-of-discharge injection], everyone's not sure who they need to be asking which questions." e Pharmacy Technician "There was initially some kind of a protocol, but I don't think it's happening, and I don't know that anybody who needs to know about it knows about it. Social workers aren't sure if they're supposed to reserve the room because I thought they were tweaking some of that. It ends up being another thing we have to run around doing at the last minute."e Social Worker
Challenges and facilitators of discharge
Healthcare team members frequently reported that the discharge process for a patient beginning use of a LAI antipsychotic varied significantly between units. Healthcare team members were only aware of the discharge procedures of their specific unit. "There's a lot of variation even from floor to floor here as far as what happens, each unit does things differently. There's no standardization, which is bad. Not knowing what actually happens at the point of discharge for a patient who doesn't receive pharmacy discharge services." e Pharmacist All patients did receive a printed discharge summary that contained a medication list and follow-up appointments, but this was described as "confusing" and easily overlooked by patients during the chaotic discharge process. Healthcare teams on each unit utilized pharmacy services differently during discharge; this led to patients receiving different amounts of information about their medicines before leaving the facility. "It's also driven by the physicians on the units. If they're very comfortable using [pharmacists] and that's part of the culture of that floor, it's going to happen. We still haven't broken through to some of the units to make it the norm." e Pharmacist
Patients that chose to have prescriptions filled in the outpatient pharmacy and delivered to their inpatient unit prior to discharge received face-to-face, comprehensive medication counseling by pharmacists. Pharmacists discussed the indication for the LAI antipsychotic prescription, side effects, and answered patients' questions. When a pharmacist was not involved in discharge, the level and content of counseling provided to patients was unclear due to a lack of standardization of information provided to patients by other members of the healthcare team.
"The counseling on [units that do not use pharmacy services] at discharge is not very in depth, they're just basically telling them, 'These are the medications that you have prescriptions for'." e Pharmacist Pharmacists expressed interest in providing more discharge medication counseling, but underutilization of their services and staffing limitations prevented further expansion of this service.
"So, in the perfect world all discharges that leave [the hospital] would go through the [pharmacy] program. But we're not there yet. We do about 25% of discharges."e Pharmacist "I think really having that touch point with a pharmacist at discharge, and reviewing each of the medications. I think that's really important. So I wish we could discharge counsel every patient." e Pharmacist Healthcare team members suggested that a challenge of the discharge process was the lack of communication and coordination between the inpatient and outpatient teams. Though pharmacist involvement improved communication, outpatient healthcare team members reported they were only notified of LAI antipsychotic initiation nearing discharge, causing difficulty in arrangements of closely scheduled outpatient follow-up and injection appointments.
"We are concerned that sometimes it is not soon enough. That's been one of our on-going complaints, we kind of feel that it's right before discharge." e Psychiatrist "Big-time disconnect between the inpatient and the outpatient. There are still times where [outpatient] is still asking for information the day of discharge or even after discharge."ePharmacist "I don't know what's happening inpatient. I have to ask a thousand questionsdand they sometimes still don't answer the questions." e Outpatient Team Member A similar communication barrier that affected patient discharge is that social workers were not always aware of the decision to initiate a LAI antipsychotic, or when the injection would be administered to the patient. "What's not been easy lately is kind of the communication between team members about the intent to start somebody on [a LAI antipsychotic]. And it's not always clear to the social workers that that's a plan. I think sometimes the residents and the doctors are aware of it, but they don't communicate it to the social worker, consistently."e Social Worker "There's something wrong with that process if a social worker doesn't know that a long-acting injectable is going to be started." e Outpatient Team Member
Challenges and facilitators of outpatient treatment
Healthcare team members reported that the appropriate communications were not always made during outpatient treatment planning. While outpatient planning was improved as a result of pharmacist consultation requirements, the plan was often incomplete during the submission to the pharmacy for approval. This may be due to the misunderstanding of roles in outpatient treatment. When appropriate communications were not made, all outpatient treatment planning typically fell on a few healthcare team members.
"Because a lot of times they were just getting that initial injection inpatient, and then being lost to follow-up, and it was just kind of a waste. Hopefully having that follow-up injection appointment outpatient helps some of these things." e Pharmacist "I think the outpatient piece, getting that all that set up needs the most improvement."e Pharmacist
The outpatient team desired involvement in the care coordination process as soon as the decision was made to initiate a LAI antipsychotic, and suggested that an e-mail from the inpatient team at this time would improve communication. Outpatient team members had minimal involvement in inpatient decisions and were often unable to discuss concerns with inpatient psychiatrists who had prescribed a LAI antipsychotic. This caused disconnected communication as the outpatient team sought to continue the intended treatment following discharge, with a decreased likelihood of a smooth transition of care for the patient. Participants reported that some units were more engaged with the outpatient team than other units.
"As soon as inpatient knows, as soon as it's written in the [EHR]
that there's going to be a LAI, [outpatient] should have a phone call or an e-mail." e Outpatient Team Member "It would be nice if we were aware and we could discuss the case with the inpatient doctor if there were concerns. Sometimes I find that there are a few cases on inpatient when I see people starting on long-acting injectables that I sort of wonder why that was done."e Psychiatrist
The inpatient insurance verification during the pharmacist consultation was a positive change noted by one healthcare team member that reduced issues with medication cost and prior authorizations during outpatient treatment.
"Nobody shows up at a pharmacy for their outpatient injection and gets told, 'Oh, that's going to cost you $300,' or 'That's not covered. It needs a prior authorization.' And then they can't get it because the prior authorization still wasn't put in place. That stuff, in theory, doesn't happen anymore." e Pharmacist During the post-discharge period, before patients established care with the outpatient team, participants reported there was not a standardized process for follow-up.
"People could fall through the cracks, because there's no standardization." e Pharmacist Healthcare team members did not have a clear understanding of roles and responsibility regarding follow-up with patients in outpatient, including those who missed their first outpatient appointment.
"In the past, nobody was really following up very well, and we were having patients that were getting an injection here, [but] were never following up as an outpatient."e Pharmacist "I think this is where we have the most pushbackdis the outpatient follow-up." e Pharmacist Outpatient team members proposed that it was the responsibility of the inpatient team, since outpatient care was yet to be established.
"They have not seen an outpatient doctor, so inpatient is still responsible." e Outpatient Team Member A few outpatient team members recalled instances when they had alerted the inpatient team of a missed appointment. However, inpatient team members suggested that the outpatient team was responsible for following up with patients by telephone postdischarge, but this did not routinely take place; the lack of established roles and a standardized process led to deficient follow-up practices in the outpatient setting.
"And even once they're discharged it's more on the outpatient side of things. It's rare inpatient is doing too much." e Psychiatrist "Outpatient may sometimes send us an e-mail and say, '[the patient] didn't show up.' But that's rare. Sometimes they will, sometimes they won't. But that's really up to them to deal with. Unless they think we can help." e Social Worker A trained nurse at the outpatient pharmacy administered LAI antipsychotics to patients who remained within the hospital network after discharge. Pharmacists and nurses in the outpatient setting reported that a brief checklist of side effects (created by the healthcare team using medication literature) were reviewed with the patient prior to LAI administration. However, it was unclear to the nurses what degree of reported side effects would warrant not administering an injection. This resulted in patients with reported side effects inappropriately receiving injections.
"I had one patient who, I unfortunately didn't know him well, he was new to me, and he was having side effects. I thought it was his baseline. But I gave him his injection, and after that they ended up stopping the medicine because he was having so many side effects." e Injection Nurse
Pharmacists expressed a desire to be more involved with preinjection assessments, however there is currently no process in place to do this.
"Having some sort of a check-in before they get their injection with the clinical pharmacist, make sure they're not having side effects, tolerating it, because that's a big thing with adherence if they are having side effects with the medication they're going to start missing injections. They're not going to want to take it. We had one patient just recently who was on paliperidone and was super akathetic, just getting up, jumping all over the place and she had just gotten [her injection] right before that appointment. So now there's a whole extra month she's going to have to suffer with these side effects."e Pharmacist
The outpatient pharmacy staff reported that sometimes they did not receive the LAI antipsychotic prescriptions when pharmacy services were not used at discharge. It was suggested that this may be caused by the limit of one pharmacy listed in the inpatient EHR at one time, therefore if the correct outpatient pharmacy is not selected in the EHR, the prescription is sent to the wrong location. When prescriptions were missing at the outpatient pharmacy, it resulted in long wait times for patients to receive the LAI antipsychotic.
"So there is sometimes confusion [with] where the electronic prescription is sent, it has something to do with the medical record. It auto-populates, so you actually have to go in and change the pharmacy.
[Or] it goes on the previous [pharmacy] ."
e Pharmacist "Not everybody goes directly and sees a psychiatrist within that first week or two after discharge, so that's why it falls on responsibility of the inpatient psychiatrist to make sure there's a prescription for at least one to two injections [at the outpatient pharmacy]."e Pharmacist Participants reported environmental factors that influence patient compliance to LAI antipsychotics such as transportation and varying degrees of family/social support.
"Access, transport. It's more like a social work kind of deal." e Pharmacist Patient-related factors that were identified included resistance to medications and medication changes, and lack of understanding of their SMI. One healthcare team member suggested that a patient's age may also play a role in determining compliance to LAI antipsychotics, as older adult patients are typically discharged with more outpatient social support in place and tend to have more lifetime experience taking LAI antipsychotics than younger patients; however, they may have more significant disease progression and comorbidities.
"I think [we need] to just consider the geriatric population a little bit differently in terms of we usually have more things in place for them in terms of [oversight] outside the hospital." e Nurse
Patient characteristics and experiences
Six patients treated with a LAI antipsychotic were interviewed. Most of the patients reported they had received the first injection of their LAI antipsychotic during inpatient treatment. Patients reported a duration of use between three and five months and almost all received injections once monthly. Only one patient reported missing an injection due to being out of town and received it within three days upon their return. Most of the patients did not know the name of their LAI antipsychotic or provided an incorrect name. More than half of participants could not recall receiving medication counseling and were unable to specify who provided the information. Two patients reported receiving discharge counseling, one was provided a handout on side effects and the other received verbal medication counseling from a healthcare team member. Patients preferred the injectable form due to ease of administration and most reported they were "very sure" that the LAI medication treated their health condition. Participants welcomed additional information from pharmacists when they had questions about their LAI antipsychotics, particularly regarding side effects or the medication's mechanism of action. Most patients did not report any challenges with use of a LAI antipsychotic; two patients stated they experienced challenges with side effects and transportation to the facility. None of the patients expressed difficulty in paying for their LAI antipsychotics.
Discussion
Project findings indicate that healthcare team members have encountered challenges with the LAI care coordination process, which involved pharmacist consultation, in-hospital LAI administration, discharge planning, and outpatient treatment. Challenges and facilitators of the LAI care coordination process were reported by healthcare team members within the person(s), organization, tools and technology, tasks, and environment components of the SEIPS model (Fig. 1) . Prominent challenges identified by participants included miscommunication, limited knowledge of LAI antipsychotics and the care coordination process, and a lack in standardization of healthcare team members' roles. Facilitators of LAI care coordination included improved communication, use of the EHR, and inpatient pharmacy insurance verification. Most patients did not know the name of their LAI antipsychotic and did not recall that they received medication counseling. Pharmacist involvement may address some of the unique challenges faced by healthcare team members during LAI care coordination, patientreported knowledge deficits about their LAI antipsychotic, and minimal medication counseling. Challenges encountered during LAI care coordination may be reduced with an increased understanding of appropriate roles and improved communication between healthcare team members.
Recommendations for pharmacist involvement in LAI care coordination
Increased pharmacist involvement in care coordination for patients taking LAI antipsychotics may improve the process between inpatient and outpatient care. Pharmacists reported they desired more involvement in care coordination of patients taking LAI antipsychotics. Participants reported the mandatory pharmacist consultation at the beginning of LAI antipsychotic treatment was beneficial because it increased communication between pharmacists and other healthcare team members. Direct communication allowed for a smoother coordination process, though it may potentially be time consuming. All healthcare team members were aware that the inpatient pharmacy verified insurance coverage for the LAI antipsychotics prior to administering the first injection. This proactively prevented administering the first injection to patients who were unable to afford continuation of therapy and potential gaps in medication adherence once discharged to outpatient care.
Psychiatrists that routinely utilized the pharmacy transitions in care program stated that this service was beneficial. The program involved pharmacists providing direct medication counseling prior to discharge, delivery of medications to the inpatient unit, and verifying insurance coverage before processing LAI antipsychotics. Patients were required to have an outpatient injection appointment scheduled prior to inpatient or day-of-discharge injection administration, and the date and time of the appointment was provided to the patient on their discharge summary. Healthcare team members recommended that having the appointment already scheduled at discharge made it easier for patients to follow-up and increased the likelihood that they would continue LAI antipsychotic therapy in the outpatient setting.
Increased pharmacist involvement, particularly during discharge, could provide patients with medication counseling and improve their understanding of their LAI antipsychotic. Pharmacists who provide LAI antipsychotic medication counseling are able to address problems with side effects and refer patients to a social worker for other types of challenges they may experience, such as transportation. Furthermore, when patients had questions about their medications, they welcomed counseling by pharmacists. Therefore, comprehensive medication counseling is needed for patients with SMI to ensure appropriate treatment with LAI antipsychotics and promote adherence. Healthcare team members reported that family/social support can influence patients' adherence to a LAI antipsychotic, so involving family members or caretakers in pharmacist-provided counseling may be an additional method of improving adherence. Future research should explore the effectiveness of pharmacist-provided medication counseling for patients discharged to home on LAI antipsychotics.
In summary, pharmacists can (1) communicate with other members of the healthcare team to ensure appropriate utilization of LAI agents; (2) provide education on LAI antipsychotics for patients and other healthcare team members; (3) verify insurance coverage; (4) perform pre-injection patient assessments before each LAI administration; and (5) follow-up with patients discharged from the hospital with a LAI antipsychotic and those who missed their first outpatient injection appointment. Further involvement of pharmacists in care coordination to potentially reduce gaps in care of patients taking LAI antipsychotics may improve the LAI care coordination process and quality of patient care.
Implementation considerations for the pharmacist consult intervention
Given the potential benefits of pharmacist involvement/intervention in LAI care coordination, consideration of how best to support implementation and sustainment of the intervention is warranted. While data collection did not explicitly focus on implementation issues, project results uncovered many implementation-focused implications. To assist in the interpretation and presentation of these implications, a commonly-used implementation framework, the Consolidated Framework for Implementation Research (CFIR) was applied. 26 The CFIR is a wellestablished framework often used to guide "diagnostic analyses" of implementation potential of interventions in specific contexts. It classifies a range of implementation constructs across five domains which the literature indicates can be influential to implementation outcomes. The five CFIR domains are: characteristics of the intervention and individuals involved, outer and inner settings, and the implementation process. 26 Within each domain are several constructs seen as important to "what works and why." The discussion below highlights the CFIR constructs implicated by our analyses, and they are presented in italicized text. Within the domain of intervention characteristics, the perceived complexity of the intervention was a key factor in interviews with healthcare team members, such as the increasing workload of the pharmacy staff, psychiatrists, nurses, and social workers coordinating the initiation of a LAI antipsychotic. Minimizing the complexity and reducing the number of steps involved when possible may improve the perceptions of involved healthcare team members and promote uptake of the intervention.
With the domain of characteristics of individuals, knowledge and beliefs about the intervention, readiness for change, and self-efficacy to perform the functions of the intervention all emerged as important factors for impact of implementation. For instance, psychiatrists and nurses in this project were hesitant of increased pharmacist involvement during the consult for a LAI antipsychotic; this is because key stakeholders may be at different levels of readiness for change. The individual's current knowledge and behavior about the care coordination process before the intervention was implemented may therefore influence the intervention's receptivity. Some healthcare team members also noted a deficiency in other healthcare team members' knowledge of appropriate LAI antipsychotic use and the care coordination process. Such knowledge gaps could be improved by providing appropriate educational training on LAI antipsychotic use (drug information, appropriate use, timing of initiation, etc.) to healthcare team members involved in the intervention and overall care coordination process, and by informing them about the purpose and functions of the intervention and their respective roles.
With the outer setting domain, understanding of patient needs and resources is necessary to improve the continuum of LAI care coordination and promote optimal patient care. Patient needs and resources may vary based on accessibility of other healthcare settings and should be considered when implementing this or a similar intervention.
The inner setting domain, which includes structural characteristics such as units/departments and division of labor, will significantly affect implementation of this intervention. 26 Specific roles of healthcare team members, indicative of culture and implementation climate with the inner setting domain, were often not clear; this finding suggests that a standard protocol describing each team member's role and the division of labor during care coordination is needed to make a more cohesive and coordinated healthcare team. Networks and communication within the structure of the organization is another vital aspect of effective implementation. Effective communication was a significant challenge in the LAI care coordination process. Lack of communication often began when psychiatrists sought to initiate LAI antipsychotic therapy with a patient and there was limited interaction between inpatient and outpatient services. Early communication with the outpatient team was found to be necessary for optimizing therapy and patients' compliance to LAI antipsychotics; however, the outpatient team was often notified too late. Improved communication directly between members of the healthcare team and complete patient treatment plans may conserve time and promote continued adherence.
Though not captured to a great extent in this project, available resources such as costs, technology (effective EHR systems), and staffing associated with the intervention may influence implementation in other settings. Increased staff support and remuneration for pharmacists and/or other healthcare team members should be considered prior to implementation.
Implementation of this intervention during the project involved three CFIR constructs associated with the domain of process; planning, engaging (e.g., education, training, role modeling), and reflecting and evaluating (e.g., providing feedback about progress and quality). 26 Future implementation in new locations should expect to be supported by these activities as well. This intervention will likely need adaptation for use in other contexts, which will involve additional planning (or re-planning) for each context. Reflecting and evaluating post-intervention implementation will be necessary to refine and improve the intervention for future use and continual adaptation. The strengths of this project include the participation of healthcare team members with various roles who provided insight on the intervention and areas for improvement. Triangulation of data from key informant interviews with relevant stakeholders and chart reviews provided an in-depth understanding of the overall LAI care coordination process, and project findings may inform future implementation of a pharmacist consult intervention in other healthcare contexts. The findings obtained from this project provide important key stakeholders' perspectives on optimal implementation of a pharmacist consult intervention, including challenges and facilitators that improve care coordination for patients receiving a LAI antipsychotic. Results from this project are valuable to support implementation and sustainability of a pharmacist consult intervention for future research in other healthcare systems or contexts.
Limitations
Limitations of this project include the short timeframe for data collection and the small number of patients interviewed. Patient recruitment was difficult because the majority of patients did not arrive on time for their scheduled appointment. Due to time constraints, the research team was only present during the patients' scheduled appointments though patient arrivals were unpredictable.
Conclusions
There are several challenges in LAI care coordination as patients transition from hospital to home, which may result in negative treatment experiences and patient outcomes. Challenges include lack of communication, limited standardization of roles, and inadequate knowledge of LAI antipsychotics and the care coordination process. Increased pharmacist involvement in LAI care coordination may contribute to bridging gaps in medication adherence to optimize treatment outcomes for these patients. Recommendations identified should be explored as a potential opportunity to expand pharmacists' roles and promote implementation of a pharmacist consult intervention in other healthcare settings. More in-depth examinations of challenges faced in the outpatient setting for optimal care for patients on LAI antipsychotics is needed to promote effective follow-up practices and patients' adherence to medication therapy. Additionally, future implementation-focused research could refine and investigate strategies for optimal implementation and sustainability of the pharmacist intervention.
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